Retatrutide is a 39-amino-acid synthetic peptide engineered as a triple agonist — binding GLP-1, GIP, and glucagon receptors from a single molecule. The next-generation evolution after tirzepatide, currently in late-phase clinical development. Supplied as a lyophilized powder with 3rd-party HPLC verification and full Certificate of Analysis per lot.
Retatrutide is described in published literature as the first unimolecular triple agonist of the GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly following the success of tirzepatide, it represents the current leading edge of multi-receptor incretin pharmacology.
The addition of glucagon receptor activity — on top of GLP-1 and GIP — is the molecular feature that distinguishes retatrutide from all prior incretin analogs. Glucagon receptor agonism, historically considered counter-productive for glycemic control, has been re-examined in recent research for its effects on energy expenditure and hepatic lipid metabolism.
Published pharmacology studies describe retatrutide as a 39-residue synthetic peptide with balanced agonist activity at all three target receptors. The GLP-1 and GIP arms mirror tirzepatide's dual-agonist profile. The glucagon arm adds a reported third axis of metabolic action, with published work describing distinct downstream effects on hepatic metabolism and thermogenesis.
Retatrutide is currently in Phase 3 clinical development (TRIUMPH program). It is not yet an FDA-approved drug. Published Phase 2 data (NEJM 2023) reported substantial weight reductions at the highest doses studied, which generated considerable interest in both the medical and research communities.
Supplied as a white to off-white lyophilized powder with a molecular weight of approximately 4,735 Da. Reported solubility is in bacteriostatic water or sodium chloride 0.9%. Reported terminal half-life of approximately six days, supporting the molecule's design for once-weekly administration in clinical trials.
The above summarizes published research literature. Retatrutide is an investigational compound. This is not medical advice, a protocol, or a recommendation for use. This compound is supplied for laboratory research only.
Every lot is tested by an independent 3rd-party analytical laboratory before release. The standard analytical panel includes reverse-phase HPLC (minimum 99.5% release spec, typically >99.9%), mass spectrometry for identity confirmation, Karl Fischer for water content, LAL assay for endotoxin (<0.25 EU/mL), bioburden, and sterility testing per USP <71>.
The resulting Certificate of Analysis PDF is attached to every order and is lookup-able by lot number after the fact.
Tirzepatide is a dual agonist — it binds GLP-1 and GIP receptors. Retatrutide is a triple agonist — it adds the glucagon receptor to that pair. The glucagon arm is the key structural and pharmacological addition; published research describes it as contributing distinct effects on energy expenditure and hepatic metabolism.
The other key difference is regulatory status. Tirzepatide is FDA-approved (Mounjaro, Zepbound). Retatrutide is investigational — still in Phase 3 trials as of 2026.
Shipped at ambient temperature in discreet, tamper-evident packaging. Lyophilized peptide powder is stable at room temperature for typical transit windows, which is why research-grade vendors ship this way without cold-chain logistics. Tracked via carrier; signature not required.
Upon receipt, store the unopened lyophilized vial refrigerated at 2–8°C and protected from light. Literature reports the lyophilized form is stable for up to 24 months under these conditions. If reconstituted per published solubility data, the solution is typically stable for approximately 28 days at 2–8°C. Do not freeze.
Retatrutide is a 39-amino-acid synthetic peptide with a molecular formula of C259H385N65O78 and a molecular weight of approximately 4,735 Da. It carries a C18 fatty diacid lipid modification at the K17 position, enabling albumin binding and extended half-life similar to the design strategy used in tirzepatide.
Supplied as a white to off-white lyophilized powder. The full primary structure and reference data are in the Compound Profile section above.
All compounds are synthesized by qualified partner laboratories operating under standard peptide synthesis practices. Synthesis records, raw material provenance, and release testing are documented in the lot file.
Each lot is independently verified by a 3rd-party analytical lab — not our in-house testing — before release. The COA PDF identifies the release lab, the method, and the analyst.
Domestic US shipping to all 50 states via USPS / UPS. Tracking provided at dispatch. International shipping is evaluated on a case-by-case basis due to jurisdictional import regulations.
All products offered on this site are intended for laboratory research purposes only. They are not for human consumption, oral ingestion, or any form of in-vivo use in humans or animals. These compounds are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease.
By placing an order you acknowledge that you are a qualified researcher over the age of 21 and that you assume all responsibility for handling, storage, and end use of the compounds in accordance with applicable law.
HPLC-verified. Mass-spec confirmed. Ambient-stable transit. The paperwork other vendors hope you never ask for.
⚠ ALL PRODUCTS ARE INTENDED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION, ORAL INGESTION, OR ANY FORM OF IN-VIVO USE IN HUMANS OR ANIMALS. THESE COMPOUNDS ARE NOT MEDICINES OR DRUGS AND HAVE NOT BEEN APPROVED BY THE FDA. BY PLACING AN ORDER YOU ACKNOWLEDGE YOU ARE A QUALIFIED RESEARCHER OVER THE AGE OF 21.